ArticleNPJ Parkinson's disease2022
Linking the phenotype of SNCA Triplication with PET-MRI imaging pattern and alpha-synuclein CSF seeding.
Article in NPJ Parkinson's disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 23 citations in OpenAlex.
- α-Synuclein regulates monoamine transporter capacity and amphetamine-induced efflux via modulation of transporter expression.The Journal of pharmacology and experimental therapeutics · 2026Article
- SNCA triplication disrupts proteostasis and extracellular architecture prior to neurodegeneration in human midbrain organoids.NPJ Parkinson's disease · 2026Article
- Pathway Analysis and Genetic Markers in Parkinson's Disease: Insights into Subtype-Specific Mechanisms.Molecular neurobiology · 2025Article
- Exploring the Application Potential of α-Synuclein Molecular Probes in Early Diagnosis of Parkinson's Disease: Focus on Imaging Methods.ACS chemical neuroscience · 2025Review
- α-Synuclein Pathology Spreads in a Midbrain-Hindbrain Assembloid Model.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- The α-Synuclein Seeding Amplification Assay for Parkinson's Disease.International journal of molecular sciences · 2025Review
- Non-motor symptoms of Parkinson`s disease-insights from genetics.Journal of neural transmission (Vienna, Austria : 1996) · 2024Review
- A systematic review of the challenges, emerging solutions and applications, and future directions of PET/MRI in Parkinson's disease.EJNMMI reports · 2024Review
- CSF α-synuclein seed amplification kinetic profiles are associated with cognitive decline in Parkinson's disease.NPJ Parkinson's disease · 2024Article
- Abdominal multi-organ iron content and the risk of Parkinson's disease: a Mendelian randomization study.Frontiers in aging neuroscience · 2024Article
- Combining Biomarkers with Genetics In Prodromal/Earliest Phase Parkinson's Disease.Journal of Parkinson's disease · 2024Review
- Characterization ofMovement disorders clinical practice · 2023Review
- Imaging Markers in Genetic Forms of Parkinson's Disease.Brain sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lewy-body pathology with aggregation of abnormal conformations of the protein alpha-synuclein (α-Syn) represent the histopathological hallmarks of Parkinson's disease (PD). Genetic prototypes such as PD due to mutations in the alpha-synuclein gene (SNCA) offer the opportunity to evaluate α-Syn-related profiles in patient-derived biomaterial. We identified a family with a SNCA triplication and assessed the index patient for CSF α-Syn seeding capacity and levels of total α-Syn along with other neurodegenerative CSF markers (Aβ
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.